TabletsClinical Overview
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once or twice daily after meals with a full glass of water. Swallow prolonged-release tablets whole; do NOT crush, split, or chew. Take consistently with food to avoid gastric irritation.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, epigastric distress, headache, insomnia, restlessness, tachycardia, tremors, gastroesophageal reflux. Rare/Severe: Cardiac arrhythmias, intractable seizures, and hypokalemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Narrow therapeutic index; monitor serum theophylline levels if high doses are used. Clearance is decreased by ciprofloxacin, erythromycin, cimetidine, and heart failure (increasing toxicity risk). Contraindicated in active peptic ulcer disease and uncontrolled epilepsy.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Etophyllin 77mg + Theophylline 23mg Tablets
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Etophylline 115mg + Theophylline 35mg Prolonged Release Tablets
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Theophylline Prolonged-release Tablets 400 mg
Etophylline and Theophylline Tablets (77mg/23mg, 115mg/35mg PR, 231mg/69mg PR, 400mg Theophylline PR) is an oral methylxanthine bronchodilator on the WHO Model List of Essential Medicines. Etophylline enhances the water solubility and gastric tolerance of theophylline. Inhibits phosphodiesterase and antagonizes adenosine receptors to provide continuous bronchodilation and enhance diaphragmatic muscle endurance. Indicated for long-term maintenance of reversible bronchospasm in bronchial asthma, chronic bronchitis, and COPD.
Etophyllin 84.7mg + Theophylline 25.3mg Injection per ml
Etophylline (84.7mg) and Theophylline (25.3mg per ml) Injection (Deriphyllin) is a parenteral methylxanthine bronchodilator combination on the WHO Model List framework. It non-selectively inhibits phosphodiesterase (PDE) enzymes, elevating intracellular cyclic AMP, competitively antagonizes adenosine A1 and A2 receptors, and stimulates endogenous catecholamine release. This produces relaxation of bronchial smooth muscle, stimulates the medullary respiratory center, improves diaphragmatic contractility, and exerts mild diuresis. Indicated for acute relief of severe bronchospasm in bronchial asthma, status asthmaticus, chronic bronchitis, and left ventricular failure with pulmonary edema (cardiac asthma).